Stockreport

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy May 23, 2024 6:32 AM ET 1 Like [Seeking Alpha]

89bio, Inc.  (ETNB) 
Last 89bio, inc. earnings: 3/18 04:05 pm Check Earnings Report
PDF Their drug candidate, pegozafermin, has shown positive results in reducing liver fat and insulin resistance and is in phase 3 trials for metabolic dysfunction-associate [Read more]